Roche’s New Breast Cancer Drug Gets US FDA Nod; Is India’s Regulatory Approval Next?

Published on:

Roche’s breast cancer drug giredestrant wins US FDA approval, offering new hope for patients with advanced, ESR1-mutated cancer. India’s next step could bring new treatment opportunities, supported by regulatory approval, affordability and wider access.

Roche new oral breast cancer drug, Wilserdly
Roche’s New Breast Cancer Drug Gets US FDA Nod; Is India’s Regulatory Approval Next?

In a significant development in breast cancer treatment, Swiss pharmaceutical major Roche has received a US Food and Drug Administration (FDA) nod for its new oral breast cancer drug, Wilserdly (giredestrant). The drug is approved for use with everolimus. It is meant for patients with advanced breast cancer whose disease no longer responds to hormone-based treatment.

The approval could open up a new treatment avenue for a group of patients who often have limited options after their cancer develops resistance to existing therapies. The combination is specifically approved for adults with oestrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The biggest finding comes from the global phase III evERA clinical trial. Among patients whose tumours carried ESR1 mutations, the drug combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy combined with everolimus.

The findings are particularly relevant because ESR1 mutations are estimated to occur in up to 40% of patients with hormone receptor-positive metastatic breast cancer and are a major reason why hormone-based treatments eventually stop working.

The development assumes significance for India, too, where breast cancer is the most common cancer among women. According to estimates from India's National Cancer Registry Programme, nearly 2.39 lakh new breast cancer cases were projected for 2025.

For Indian patients, the drug represents a potential new option at a particularly difficult stage of treatment — when cancer progresses despite earlier hormone therapy and CDK4/6 inhibitor treatment.

Unlike some existing treatments that require injections, giredestrant is an oral selective oestrogen receptor degrader (SERD). It works by blocking the oestrogen receptor and triggering its breakdown, thereby disrupting signals that help certain breast cancer cells grow.

When combined with everolimus, which acts on a separate cancer-growth pathway, the treatment targets two mechanisms involved in tumour progression and treatment resistance.

The oral format could also offer greater convenience by allowing patients to take treatment at home, potentially reducing the need for frequent hospital visits. However, the combination still requires medical supervision, monitoring and management of possible side effects.

The US FDA approval does not automatically make Wilserdly available in India. The drug will need the necessary Indian regulatory clearances before it can be marketed for this indication.

Its eventual impact will also depend on its price, availability of ESR1 mutation testing and access to specialist oncology services. Since the treatment is intended for patients with a specific genetic mutation, identifying eligible patients through appropriate testing will be crucial.

For India, where the cost of advanced cancer treatment can be a major concern for families, affordability could determine how widely such an innovation is adopted.

The drug's approval is also not a cure for breast cancer. The trial demonstrated a significant delay in disease progression, not proof that the treatment eliminates the disease or improves overall survival.

Roche is also awaiting a separate FDA decision on giredestrant as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. A decision is expected by November 30, 2026.

If approved, it could expand the drug's role beyond advanced disease to patients receiving treatment after surgery to reduce the risk of cancer returning.

For India, the larger significance is the growing shift towards precision oncology — selecting treatment based not only on the organ affected by cancer but also on the specific genetic changes driving its growth and resistance.

×